KBI Biopharma is a biologics CDMO providing process development, analytical development, formulation, microbial manufacturing, mammalian cell culture, and clinical manufacturing services. The company serves biotechnology and pharmaceutical sponsors developing proteins, antibodies, and other biologics.

KalVista Pharmaceuticals is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Rare Disease & Orphan Drug Developers 1 ranking category Overview

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on neuroscience, sleep medicine, oncology, and rare disease. The company’s commercial identity has been shaped by specialist-managed neurological and sleep disorders, as well as selected oncology products.

Ironwood Pharmaceuticals is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Specialty Pharma Companies 1 ranking category Overview

IQVIA is one of the most important Contract Research Organizations globally, combining large-scale clinical development services with healthcare data, analytics, real-world evidence, consulting, and technology platforms. Its position is distinctive because it operates not only as a CRO, but also as a healthcare information and analytics company serving pharmaceutical, biotechnology, payer, provider, and government clients.

Ipsen is a European specialty pharmaceutical company with strong focus in oncology, rare disease, and neuroscience. The company’s business model is clearly aligned with specialist physician markets and clinically differentiated therapies.

Ionis Pharmaceuticals is one of the most important RNA medicine companies in rare disease development. The company’s antisense oligonucleotide platform has contributed to approved medicines and partnerships across neurological, metabolic, cardiovascular, and rare genetic disease areas.

Intellia Therapeutics is a leading developer of in vivo CRISPR-based therapies. Unlike ex vivo approaches that modify cells outside the body, Intellia’s platform is focused on delivering gene editing components directly into patients, particularly for liver-expressed disease targets.

Inovio Pharmaceuticals is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Vaccine & Immunotherapy Developers 1 ranking category Overview

Incyte is an established specialty pharmaceutical company focused on oncology, hematology, inflammation, and dermatology. Its commercial foundation is built around specialist-managed disease areas, particularly hematologic malignancies and targeted therapies.

ICON plc is one of the world’s largest full-service CROs, with major capabilities across clinical trial management, site and patient services, data management, biostatistics, pharmacovigilance, regulatory affairs, decentralized trial support, and real-world evidence. Its acquisition of PRA Health Sciences significantly expanded its global scale and therapeutic coverage.

Harmony Biosciences is a specialist pharmaceutical company focused on rare neurological and sleep-wake disorders. Its core commercial activity has been associated with narcolepsy, a rare neurological disorder involving excessive daytime sleepiness and cataplexy.

Halozyme Therapeutics is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Biotechnology Firms 1 ranking category Overview

GSK is one of the world’s leading vaccine developers and one of the most institutionally important companies in preventive immunization. Its vaccine business spans shingles, RSV, meningococcal disease, influenza, hepatitis, pediatric vaccines, and other infectious disease categories.

Grifols is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Global Pharmaceutical Companies 1 ranking category Overview

Gilead Sciences remains one of the most important biotechnology firms globally, with a defining position in antiviral medicine and expanding activity in oncology, cell therapy, and inflammation. The company’s institutional identity has been shaped by scientific and commercial leadership in HIV and hepatitis treatments.

Genmab is one of Europe’s leading biotechnology firms and a major global player in antibody-based therapeutics. The company is known for its antibody technology platforms, oncology focus, and partnerships with larger pharmaceutical companies.

FUJIFILM Diosynth Biotechnologies is one of the fastest-rising global biomanufacturing and CDMO providers, with major capabilities in biologics, vaccines, advanced therapies, microbial fermentation, mammalian cell culture, process development, and commercial manufacturing.

Fortrea is a major global CRO formed from the clinical development and patient access businesses formerly associated with Labcorp. The company provides clinical trial management, pharmacovigilance, regulatory affairs, data management, clinical pharmacology, and related development services for pharmaceutical and biotechnology sponsors.

Fate Therapeutics is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Cell & Gene Therapy Developers 1 ranking category Overview